Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aims: To investigate the impact of patiromer on the serum potassium level and its ability to enable specified target doses of renin–angiotensin–aldosterone system inhibitor (RAASi) use in patients with heart failure and reduced ejection fraction (HFrEF). Methods and results: A total of 1642 patients with HFrEF and current or a history of RAASi-related hyperkalemia were screened and 1195 were enrolled in the run-in phase with patiromer and optimization of the RAASi therapy [≥50% recommended dose of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor-neprilysin inhibitor, and 50 mg of mineralocorticoid receptor antagonist (MRA) spironolactone or eplerenone]. Specified target doses of the RAASi therapy were achieved in 878 (84.6%) patients; 439 were randomized to patiromer and 439 to placebo. All patients, physicians, and outcome assessors were blinded to treatment assignment. The primary endpoint was between-group difference in the adjusted mean change in serum potassium. Five hierarchical secondary endpoints were assessed. At the end of treatment, the median (interquartile range) duration of follow-up was 27 (13–43) weeks, the adjusted mean change in potassium was +0.03 mmol/l in the patiromer group and +0.13 mmol/l in the placebo group [difference in the adjusted mean change between patiromer and placebo: −0.10 mmol/l (95% confidence interval, CI −0.13, 0.07); P < 0.001]. Risk of hyperkalemia >5.5 mmol/l [hazard ratio (HR) 0.63; 95% CI 0.45, 0.87; P = 0.006), reduction of MRA dose (HR 0.62; 95% CI 0.45, 0.87; P = 0.006), and total adjusted hyperkalemia events/100 person-years (77.7 vs. 118.2; HR 0.66; 95% CI 0.53, 0.81; P < 0.001) were lower with patiromer. Hyperkalemia-related morbidity-adjusted events (win ratio 1.53, P < 0.001) and total RAASi use score (win ratio 1.25, P = 0.048) favored the patiromer arm. Adverse events were similar between groups. Conclusion: Concurrent use of patiromer and high-dose MRAs reduces the risk of recurrent hyperkalemia (ClinicalTrials.gov: NCT03888066).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
Self-citationEplerenone in patients with systolic heart failure and mild symptoms
Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Swedberg, K., Shi, H., Vincent, J., Pocock, S. J., & Pitt, B. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009492 · Cited by 3,111 · cited 2×
“50 mg/day of eplerenone/spironolactone, were selected as the maximum doses in the RALES and EMPHASIS-HF trials.(3,19) The pre-RALES trials found that 50 mg spironolactone produced the highest reduction in N-terminal pro-atrial natriuretic peptide,(20) which is associated with heart failure prognosis, and whilst it is…”
BackgroundMethodSelf-citationVericiguat in patients with heart failure and reduced ejection fraction
Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915928 · Cited by 1,358 · cited 1×
“18 In this regard, it is important to note that in the DIAMOND trial, 84.6% of the patients at the end of run-in phase were able to achieve ≥ 50% of target dose of the combination RAASi therapy and 97% were able to take the triple therapy at some dose.”
BackgroundInfluentialSelf-citationManaging hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system
Palmer, B. F. (2004) · New England Journal of Medicine · doi:10.1056/nejmra035279 · Cited by 640
Cited by
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208
Self-citationMaddox, T. M., Januzzi, J. L., Allen, L. A., Breathett, K., Brouse, S., Butler, J., Davis, L. L., Fonarow, G. C., Ibrahim, N. E., Lindenfeld, J., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.024 · Cited by 362
Self-citationNdumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Hyperkalemia in chronic kidney disease: a focus on potassium lowering pharmacotherapy
Sampani, E., Theodorakopoulou, M., Iatridi, F., & Sarafidis, P. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2245756 · Cited by 11
Metadata
- Authors
- Butler, J., Anker, S. D., Lund, L. H., Coats, A. J. S., Filippatos, G., Siddiqi, T. J., Friede, T., Fabien, V., Kosiborod, M., Metra, M., Piña, I. L., Pinto, F., Rossignol, P., van der Meer, P., Bahit, C., Belohlavek, J., Böhm, M., Brugts, J. J., Cleland, J. G. F., Ezekowitz, J., Bayes-Genis, A., Gotsman, I., Goudev, A., Khintibidze, I., Lindenfeld, J., Mentz, R. J., Merkely, B., Montes, E. C., Mullens, W., Nicolau, J. C., Parkhomenko, A., Ponikowski, P., Seferovic, P. M., Senni, M., Shlyakhto, E., Cohen-Solal, A., Szecsödy, P., Jensen, K., Dorigotti, F., Weir, M. R., & Pitt, B.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-08-23
- Volume
- 43
- Issue
- 41
- Pages
- 4362-4373
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W4288445068
- Cited by
- 231
- References
- 5
- FWCI
- 25.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. https://app.cochat.ai/papers/10.1093/eurheartj/ehac401
- The paper
- Butler, J., Anker, S. D., Lund, L. H., Coats, A. J. S., Filippatos, G., Siddiqi, T. J., Friede, T., Fabien, V., Kosiborod, M., Metra, M., Piña, I. L., Pinto, F., Rossignol, P., van der Meer, P., Bahit, C., Belohlavek, J., Böhm, M., Brugts, J. J., Cleland, J. G. F., . . . Pitt, B. (2022). Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehac401
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.